33
Participants
Start Date
December 13, 2017
Primary Completion Date
May 22, 2018
Study Completion Date
May 22, 2018
4 mg CLS-TA Suprachoriodal Injection
This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Sham procedure
This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
University of Pittsburgh Medical Center Eye Center, Pittsburgh
Marietta Eye Clinic, Marietta
Retina Group of Florida, Fort Lauderdale
Bergstrom Eye Research, Fargo
Texas Retina Associates, Dallas
Retina Consultants of Houston, The Woodlands
Retinal Consultants of Arizona, Phoenix
Northern California Retina Vitreous Associates Medical Group, Inc., Mountain View
Oregon Health & Science University Casey Eye Institute, Portland
Dr Rajendra Prasad Centre for Ophthalmic Sciences, New Delhi
King George's Medical University, Lucknow
Sankara Eye Hospital, Coimbatore
Disha Eye Hospitals Pvt. Ltd., Kolkata
Sri Sankaradeva Nethralaya, Guwahati
Valley Eye Physicians and Surgeons, PC, Ayer
JSS Hospital, Mysore
Lead Sponsor
Clearside Biomedical, Inc.
INDUSTRY